ERA 2026: HighTide Therapeutics Presents New Findings Supporting ...
Dialogue with HighTide Therapeutics' CMO Dr. Filip Surmont: ...
EASD 2025 | HighTide Therapeutics Announces Oral Presentation ...
HighTide Therapeutics Inc. is Invited to Present at the ...
Prediabetes Market is Projected to Boost at a Moderate Growth ...
HighTide Therapeutics to Showcase New Analyses of Phase ...
HighTide Therapeutics to Present Analyses of Phase 2 MASH ...
EASD 2024 | HighTide Therapeutics Presents Oral Reports ...
HighTide Therapeutics Presents Analyses of a Phase 2 T2DM ...
HighTide Therapeutics Presents Analyses of Phase 2a MASH ...
HighTide Therapeutics Presents Analyses of Phase 2a MASH ...